Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
Oehler
V G
VG
Qin
J
J
Ramakrishnan
R
R
Facer
G
G
Ananthnarayan
S
S
Cummings
C
C
Deininger
M
M
Shah
N
N
McCormick
F
F
Willis
S
S
Daridon
A
A
Unger
M
M
Radich
J P
JP
D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000235:genetics*; D046210:Microfluidic Analytical Techniques / Q000295:instrumentation; D036103:Nanotechnology / Q000295:instrumentation*; D017354:Point Mutation; D016133:Polymerase Chain Reaction / Q000379:methods* / Q000592:standards; D012680:Sensitivity and Specificity
D016044:Fusion Proteins, bcr-abl